CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis

• Market Cap: $267.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: N/A
• EPS Growth: 5.51%
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 51,919,320
• 10 Day Avg. Volume: 141,089
• 30 Day Avg. Volume: 1,592,597
• PEG Ratio: 6.16
• Price to Book (P/B): 3.90
• Price to Sales (P/S): 53.24
• P/FCF Ratio: -6.24
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: 0.59
• Enterprise Value/Gross Profit: 0.76
• Enterprise Value/Ebitda: -0.04
• 1Y Price Target: $7.92
• Price Target Upside: 48.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $5.50 ▲(3.19% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is held back primarily by weak financial performance (zero revenue in 2025, persistent losses, and ongoing cash burn). Technicals are a meaningful offset with strong trend and positive momentum, while valuation remains challenged due to negative earnings and no stated dividend support.

Positive Factors

Strategic collaboration with GSK

Partnering with GSK materially de-risks late-stage development and commercialization for ASO candidates: CAMP4 supplies early discovery and regRNA expertise while GSK covers clinical development, regulatory, manufacturing and commercialization, providing validation, milestone upside and royalties without CAMP4 bearing full late-stage costs.

Improved cash runway from financings

Significant financings and year-end cash of $109.5M extend runway into 2028, reducing near-term funding pressure and allowing management to advance lead programs to key clinical and preclinical milestones, increasing optionality and reducing immediate dilution risk while programs mature.

SYNGAP1 program advancing toward clinic

Progressing CMP-002 into GLP toxicology and a planned Phase 1/2 trial is a durable operational milestone: cross-species efficacy (mice and non-human primates) strengthens translational probability and, if clinical data align, could meaningfully validate CAMP4's RNA-regulating platform and unlock partnership or revenue opportunities.

Negative Factors

Zero revenue and persistent losses

Revenue dropping to zero in 2025 removes operating leverage and leaves margins unsupported; persistent multi-year net losses undermine return metrics and indicate the company cannot currently self-fund growth, heightening reliance on external capital and increasing long-term financial risk.

Consistent negative cash flow

Ongoing negative operating and free cash flow indicates structural cash burn to support R&D and operations; even with some improvement, persistent outflows constrain strategic flexibility, make sustained investment dependent on financing, and raise execution risk if cash access tightens.

Reliance on external financings

Frequent equity financings and underwritten offerings signal dependence on capital markets to fund operations; this creates dilution risk for shareholders, may pressure management to prioritize near-term liquidity over long-term R&D choices, and leaves the company exposed if market access weakens.

CAMP4 Therapeutics Corporation Business Overview & Revenue Model

Company Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

How the Company Makes Money

null

CAMP4 Therapeutics Corporation Financial Statement Overview

Summary

Financial profile is weak: income statement reflects deep, persistent losses and revenue falling to zero in 2025. Cash flow remains a multi-year cash-burn story with negative operating cash flow and free cash flow through 2025, despite some improvement in operating outflow versus 2024. Balance sheet leverage is currently low (debt-to-equity ~0.04 in 2025), but historical volatility (including negative equity in 2023) and ongoing losses keep the risk elevated.

Income Statement

Profitability is weak and deteriorating: the company is deeply loss-making across recent annual periods, with EBIT and net income remaining materially negative in 2023–2025. Revenue is minimal in 2023–2024 and falls to zero in 2025 (a -100% revenue change), which removes operating leverage and makes margins effectively unsupported by sales. A historical contrast exists in 2021–2022 when revenue was substantial, but even then net income stayed negative, highlighting persistent cost pressure and limited earnings power.

Balance Sheet

Leverage looks manageable in the most recent year, with low debt relative to equity in 2025 (debt-to-equity ~0.04) and improving capital structure versus prior years. However, the balance sheet has shown meaningful volatility: equity was negative in 2023 (raising solvency concerns at that time), and returns on equity are consistently poor due to ongoing losses (very negative in 2024–2025). Earlier years also show periods of heavy leverage (e.g., debt-to-equity above 2x in 2021–2022), indicating the company’s funding profile has shifted materially over time.

Cash Flow

Cash generation is a key weakness: operating cash flow and free cash flow are consistently negative from 2022 through 2025, indicating ongoing cash burn to support operations. While the 2025 cash burn is smaller than 2024 (operating cash outflow improves from about -$45.6M to -$29.6M), free cash flow still declines year-over-year in 2025 (negative growth), suggesting spending remains high relative to the company’s limited revenue base. The only clear bright spot is 2021, when both operating cash flow and free cash flow were positive, but that performance has not persisted.

Breakdown	Dec 2025	Dec 2024	Nov 2023	Feb 2023	Feb 2022
Income Statement
Total Revenue	3.50M	652.00K	350.00K	0.00	295.84M
Gross Profit	1.86M	652.00K	350.00K	0.00	121.89M
EBITDA	-50.42M	-51.39M	-50.20M	-44.12M	7.49M
Net Income	-80.40M	-51.79M	-49.29M	-44.19M	-31.15M
Balance Sheet
Total Assets	117.81M	78.31M	54.95M	102.55M	402.29M
Cash, Cash Equivalents and Short-Term Investments	109.52M	64.04M	38.38M	83.19M	91.11M
Total Debt	1.97M	8.65M	11.69M	12.39M	209.17M
Total Liabilities	70.10M	15.16M	178.68M	180.08M	322.11M
Stockholders Equity	47.70M	63.14M	-123.73M	-77.53M	80.18M
Cash Flow
Free Cash Flow	-29.83M	-46.00M	-44.83M	-42.57M	-17.52M
Operating Cash Flow	-29.55M	-45.56M	-44.16M	-38.54M	-4.22M
Investing Cash Flow	-243.00K	-441.00K	-678.00K	-4.03M	-7.58M
Financing Cash Flow	75.89M	71.66M	301.00K	100.16M	-2.64M

CAMP4 Therapeutics Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 5.33 is above the 20-day moving average (MA) of 4.89, above the 50-day MA of 4.72, and above the 200-day MA of 3.36, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 55.36 is Neutral, neither overbought nor oversold. The STOCH value of 38.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.

CAMP4 Therapeutics Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLMD	57 Neutral	$458.34M	―	-269.50%	―	―	37.37%
CAMP	52 Neutral	$267.90M	-2.32	-162.49%	―	―	5.51%
ARTV	52 Neutral	$136.44M	-1.25	-60.22%	―	-100.00%	-17.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INKT	48 Neutral	$45.72M	-5.39	―	―	―	21.48%
OSTX	45 Neutral	$52.82M	-2.28	-567.59%	―	―	-133.00%
BYSI	43 Neutral	$64.15M	-11.85	1.94%	―	―	―

CAMP4 Therapeutics Corporation Corporate Events

CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress

On March 5, 2026, CAMP4 Therapeutics reported its full-year 2025 financial results and corporate highlights, underscoring a strategic pivot toward its SYNGAP1 program and RNA-regulating platform. The company updated its investor presentation, advanced CMP-002 with ongoing GLP toxicology studies to support a planned global Phase 1/2 trial in SYNGAP1-related disorder as early as the second half of 2026, and generated preclinical data showing CMP-002 increased SYNGAP1 protein and rescued behavioral phenotypes in mice while boosting protein levels in relevant brain regions in non-human primates.

During 2025, CAMP4 entered a strategic research, collaboration, and license agreement with GSK to develop antisense nucleotide drug candidates for neurodegenerative and kidney disease targets, receiving $17.5 million upfront and gaining access to substantial potential milestone economics and royalties. To strengthen its balance sheet and extend its cash runway into 2028, the company completed an oversubscribed private placement providing $50 million upfront with the potential for additional proceeds, alongside a $30 million underwritten stock offering, ending the year with $109.5 million in cash and cash equivalents while recording a wider net loss of $80.4 million largely due to a non-cash derivative liability revaluation and pausing further internal investment in CMP-001 pending partnership options.

The most recent analyst rating on (CAMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics updates corporate investor presentation materials

On January 9, 2026, CAMP4 Therapeutics Corporation updated its corporate presentation for the investment community, making the revised materials available through the investors section of its website and furnishing them as an exhibit to a regulatory filing. The move reflects the company’s ongoing practice of using slide decks and presentations to provide investors with current information on its business, while clarifying that these materials are being furnished rather than formally filed under U.S. securities laws, which limits their exposure to certain regulatory liabilities and incorporation into other securities filings.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Restructures Leases and Expands Facilities

On December 22, 2025, CAMP4 Therapeutics Corporation amended its existing lease for approximately 30,760 square feet of laboratory and office space at One Kendall Square in Cambridge, Massachusetts, accelerating the termination of that lease to 30 days after the commencement of a new lease in Watertown, while securing an abatement of base rent at the Cambridge site from October 1, 2025 until the early termination date, contingent on remaining in compliance with both leases. On the same date, the company signed a new lease for about 44,000 square feet of laboratory and office space at 100 Talcott Avenue in Watertown, Massachusetts, running through June 30, 2030, with base rent starting at $40 per square foot and increasing annually, and agreed to pay a $2.1 million lease modification fee in exchange for additional rent abatement at the new site, a move that expands its footprint and restructures its real estate costs in a key biotech hub.

The most recent analyst rating on (CAMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Announces $28 Million Common Stock Offering

On December 18, 2025, CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC to offer 5,000,000 shares of its common stock at $6.00 per share, all sold by the company, with expected net proceeds of approximately $28 million and an anticipated closing on or about December 19, 2025, subject to customary conditions. The deal includes standard underwriting terms such as indemnification provisions and a 60-day lock-up restricting share sales by the company, executives, directors and certain stockholders, while allowing sales under its at-the-market program after 30 days, underscoring CAMP4’s continued reliance on equity financing to support its business and potentially affecting share liquidity and ownership dynamics in the near term.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4, GSK form RNA therapeutics collaboration agreement

On December 17, 2025, CAMP4 Therapeutics entered into a strategic research, collaboration and license agreement with GSK to discover and develop antisense oligonucleotide therapeutics targeting regulatory RNAs linked to multiple neurodegenerative and kidney disease gene targets, combining CAMP4’s regRNA mapping and RAP Platform-based ASO discovery capabilities with GSK’s global development and commercialization infrastructure. Under the deal, CAMP4 granted GSK an exclusive worldwide license to develop and commercialize resulting compounds and products, will conduct early research to deliver lead ASO series before GSK assumes full responsibility for clinical development, regulatory work, manufacturing and commercialization, and will receive a $17.5 million upfront payment plus eligibility for up to $440 million in development and commercial milestones and tiered royalties, positioning CAMP4 to monetize its RNA platform while potentially expanding its presence in neurodegenerative and renal disease markets without bearing late-stage development risk.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.